Francesco T. Mangano · Neuromagnetic high frequency spikes are a new and noninvasive biomarker for localization of epileptogenic zones
Follow
Article1 min read·Published May 2021Older

Neuromagnetic high frequency spikes are a new and noninvasive biomarker for localization of epileptogenic zones

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · May 2021 · 1 min read

In brief

In brief

This MEG study of 23 children with drug-resistant epilepsy identifies high frequency spikes (HFSs) as a novel noninvasive biomarker that specifically localizes epileptogenic zones, unlike high frequency oscillations which appear in both patients and healthy controls. The combination achieved 96% localization accuracy when validated against surgical outcomes.

Written by the GCMD Library team from the article.

Francesco T. Mangano

Objective: One barrier hindering high frequency brain signals (HFBS, >80 Hz) from wide clinical applications is that the brain generates both pathological and physiological HFBS. This study was to find specific biomarkers for localizing epileptogenic zones (EZs). Methods: Twenty three children with drug-resistant epilepsy and age/sex matched healthy controls were studied with magnetoencephalography (MEG). High frequency oscillations (HFOs, > 4 oscillatory waveforms) and high frequency spikes (HFSs, > 1 spiky or sharp waveforms) in 80-250 Hz and 250-600 Hz bands were blindly detected with an artificial intelligence method and validated with visual inspection. The magnitude of HFOs and HFSs were quantified with spectral analyses. Sources of HFSs and HFOs were localized and compared with clinical EZs determined by invasive recordings and surgical outcomes. Results: HFOs in 80-250 Hz and 250-600 Hz were identified in both epilepsy patients (18/23, 12/23, respectively) and healthy controls (6/23, 4/23, respectively). HFSs in 80-250 Hz and 250-600 Hz were detected in patients (16/23, 11/23, respectively) but not in healthy controls. A combination of HFOs and HFSs localized EZs for 22 (22/23, 96%) patients. Conclusions: The results indicate, for the first time, that HFSs are a newer and more specific biomarker than HFOs for localizing EZs because HFOs appeared in both epilepsy patients and healthy controls while HFSs appeared only in epilepsy patients.

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →